Skip to main content
Amy P. Abernethy

Amy P. Abernethy

Oncologist

Nov 14, 2026

5:42
But maybe I'll just, in that, I'll hand it to Amy to your journey, sweetie.
5:47
Yeah, so I appreciate, oh, there's a few tears.
5:50
I knew if I saw someone crying, it would make me cry.
5:54
Yeah, it's been, I just want you to know, like, we love you guys so much.
5:57
And so this decision and this journey has been very carefully weighed.
6:03
It's not been something that's been a rash decision.
6:06
And even, you know, for me, like when Brendan was first kind of starting to say, I feel like the Lord might be saying this.

20 MINS LATER

25:42
Brendan, you come in too and pray.
11:19
How does this real-world data, we've got it now, we've got this information, how is that going to help to change what we do?
11:27
As data sets now come together, so let's, for example, use a data set around people with non-small cell lung cancer, some of whom have received immunotherapy and some of whom received standard chemotherapy, and you want to understand what is the potential incremental benefit of immunotherapy.
11:45
So as these data sets first are de-identified and prepared for analysis, It allows us then to analyze and ask a question like immunotherapy as compared to standard chemotherapy, but also drill in further.
12:00
So for example, for which patients does there seem to be more of an improvement with immunotherapy over others? Maybe that's by a genetic kind of element that seems to lead to a potential proclivity towards one treatment working better than another.
12:15
Also, for example, how might this data set actually inform people who historically would never have made it into clinical trials? So for example, people who are represented in the data who have some evidence of kidney failure or liver failure, who never would have been involved in clinical trials, but now oftentimes are receiving care in routine care, and their information can also contribute to the future.
12:39
But we're moving quickly to a place where the analytic framework, both the analytic capabilities, including sort of modern scientific capabilities like causal inference and modern tools such as artificial intelligence, coupled with much more facile data preparation capabilities have gotten us to this place where we actually can start to not just do this as bulk analysis that takes six or 18 months to do each of these analyses, but we can actually do it much faster and start to have much more in real time.
13:10
Now we're not quite there yet, but that's where the story goes.

8 MINS LATER

21:28
Is AI an integral part of that process?
2:01
So can you start off by describing to us why are clinical trials seemingly faster in China? What is the source of all of this efficiency, and where are the differences most noticeable between China and the US?
2:14
It'll be helpful to go back to h- how did we get to the place where the US biomedical leadership emerged.
2:22
But first, let's talk about China and the efficiency in front of us, and how did China become a locus of clinical development.
2:30
This was due to deliberate integrated national reform.
2:33
It wasn't an organic drift, and the pivot traces back to a single policy, a state council policy in twenty fifteen called Opinions on Reform of the Review and Approval Process for Drugs and Medical Devices.
2:48
That redesigned really every stage of the development li- lifecycle, and we describe this in some detail in a Nature Medicine commentary published in June of this year.
3:02
That ten-year plan that we have seen now get put in motion, and its output has been a key driver behind the efficiency that you describe.

8 MINS LATER

10:57
Is that okay? Does that produce reliable results? How can we balance speed with safety? And it would be great if you could bring in all of your expertise, including at the FDA, to compare which parts of the US system might accelerate or slow down trials in a way that provides additional benefit or maybe less so.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.